Bayer say VEGF Trap-Eye shows promise as mCNV treatment
June 06, 2013 at 02:43 AM EDT
FRANKFURT, June 6 (Reuters) - Bayer said on Thursday its drug VEGF Trap-Eye had demonstrated to improve visual acuity in a late-stage trial on patients suffering from myopic choroidal neovascularization (mCNV).
